文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.

作者信息

Peña M, Montané C, Paviglianiti A, Hurtado L, González S, Carro I, Maluquer C, Domingo-Domenech E, Gonzalez-Barca E, Sureda A, Mussetti A

机构信息

Clinical Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain.

Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain.

出版信息

Bone Marrow Transplant. 2023 Nov;58(11):1282-1285. doi: 10.1038/s41409-023-02069-2. Epub 2023 Aug 25.

DOI:10.1038/s41409-023-02069-2
PMID:37626265
Abstract
摘要

相似文献

[1]
Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.

Bone Marrow Transplant. 2023-11

[2]
Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.

Hematol Oncol. 2017-3

[3]
Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial.

Lancet Oncol. 2014-5-11

[4]
Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy.

Biol Blood Marrow Transplant. 2006-7

[5]
Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.

Leukemia. 2014-6-18

[6]
Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Clin Lymphoma Myeloma Leuk. 2019-3-30

[7]
Immune and Cell Therapy in Non-Hodgkin Lymphoma.

Cancer J. 2020

[8]
Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia.

Hematology Am Soc Hematol Educ Program. 2006

[9]
Allogeneic transplantation for lymphoma: risk-benefit balance is in the eye of the beholder.

Biol Blood Marrow Transplant. 2014-7

[10]
Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma.

Best Pract Res Clin Haematol. 2005-3

引用本文的文献

[1]
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders.

Blood Adv. 2025-8-26

[2]
Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.

Haematologica. 2024-10-1

本文引用的文献

[1]
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

N Engl J Med. 2022-12-15

[2]
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.

Blood. 2022-9-8

[3]
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

Lancet Haematol. 2022-5

[4]
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.

J Clin Oncol. 2022-2-10

[5]
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.

Lancet. 2021-9-25

[6]
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

J Clin Oncol. 2021-6-20

[7]
Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.

Blood Rev. 2021-9

[8]
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Leukemia. 2021-9

[9]
Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry.

J Clin Oncol. 2011-2-14

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索